26 January 2012 Oryzon to Present at 4th CHI X-Gen Congress, Epigenetics, Targets and Therapies on March 6
6 February 2012 Oryzon nominates bispecific LSD1/MAOB inhibitor as drug candidate to enter preclinical development in Huntington´s Disease
8 May 2012 Oryzon to Present its LSD1 program in Acute Leukemias at the GTC’s 2nd Epigenetics in Drug Discovery conference in Boston
25 May 2012 Oryzon nominates specific LSD1 inhibitor as drug candidate to enter preclinical development in Acute leukemia and other hematological cancers
13 June 2012 Oryzon assigns Dr. Xavier Luria as Non-Executive Director of Medical and Regulatory Affairs
10 September 2012 ORYZON and CANCER RESEARCH UK’S Paterson Institute for Cancer Research have started a collaborative research project on therapeutic uses of LSD1 inhibitors for Acute Leukaemia
24 October 2014 ORYZON awarded 1,1 Million EUROS grant to develop its EPIGENETIC LSD1 inhibitors for Acute Leukemia